Propagator Cells for High-Titer Phage Production at Lower Volume
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for commercial-scale production of bacteriophages for therapeutic use face challenges in achieving high titers (1012 pfu/ml) and require large volumes, while existing techniques yield lower titers (109-1011 pfu/ml on a laboratory scale and 107-109 pfu/ml on a commercial scale.
Innovation Solution
A method and cell system for propagating phages by infecting cells of a different species or strain that express a specific cell-surface receptor, allowing for high-titer production of phages capable of targeting a first bacterial species.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current commercial-scale production methods are used, then large volumes of liquid are required, but the titer of phage composition remains low (10^7-10^9 pfu/ml)
Solution Approach 1:
The patent changes the key parameter of host cell species/strain used for phage propagation. By selecting specific propagator cells with optimized receptor expression and compatibility characteristics, the system achieves higher phage titers (10^12 pfu/ml) without proportionally increasing culture volume, directly resolving the contradiction between titer and volume
Solution Approach 2:
The patent introduces an intermediary system - specifically engineered propagator cells that serve as a bridge between phage production requirements and therapeutic application needs. These intermediary cells enable efficient phage amplification to therapeutic titers while maintaining controlled culture volumes, solving the volume-titer trade-off
2Quantity of substance
If current production techniques are used, then phage can be produced, but very large volumes of liquid are required to reach desirable titer
Solution Approach 1:
The patent optimizes multiple parameters simultaneously: selecting propagator cells with high receptor density, optimizing multiplicity of infection (MOI), and controlling culture conditions. These parameter changes collectively enable reaching 10^12 pfu/ml titer with significantly reduced culture volumes, thereby improving production efficiency
Solution Approach 2:
The patent performs preliminary selection and characterization of propagator cell lines before large-scale production. By pre-optimizing the host cell system with appropriate receptor expression levels and compatibility traits, the subsequent phage production runs achieve higher efficiency and faster kinetics, reducing the overall time and volume required
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables high-yield production of phages suitable for therapeutic use, overcoming the limitations of current methods by achieving the required titer efficiently and reducing manufacturing volume.
Implementation Method 1
The adsorption of bacteriophages onto host cells is, in all but a few rare cases, a sine qua non condition for the onset of the infection process
Data Source
AI summary
The invention provides propagator cells and methods for propagating phage and transduction particles.